Skip to main content

Table 2 Number of patients with or without pulmonary malignancy and the presence of onconeuronal, antineuronal, and welldefined onconeuronal antibodies.

From: Onconeuronal and antineuronal antibodies in patients with neoplastic and non-neoplastic pulmonary pathologies and suspected for paraneoplastic neurological syndrome

  Primary pulmonary malignancy No primary pulmonary malignancy identified
Onconeuronal and antineuronal 5 6
antibodies (n = 11) (45%) (54%)
No onconeuronal and antineuronal 6 4
antibodies present (n = 10) (60%) (40%)
Well-defined onconeuronal 3 2
antibodies (n = 5) (60%) (40%)
No well-defined onconeuronal 8 8
antibodies present (n = 16) (50%) (50%)